Confronto
DSIP vs. Goserelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
62568-57-4
65807-02-5
Peso molecolare
848.81 g/mol
1269.43 g/mol
Emivita
0.1 h
4.2 h
Sequenza
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GlupGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2Meccanismo d'azione
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
1
4
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between DSIP and Goserelin?
- DSIP is classified as "Ricerca (altro)", while Goserelin is classified as "Ricerca (altro)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Goserelin?
- The highest available evidence level is "Studio sull'uomo" for DSIP and "RCT sull'uomo" for Goserelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Goserelin in Germany and the United States?
- Germania: DSIP — Non approvato, Goserelin — Su prescrizione. Stati Uniti: DSIP — Non approvato, Goserelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.